On Monday, GRAIL reached an important technical milestone, seeing its Relative Strength (RS) Rating jump into the 90-plus percentile with an improvement to 94, up from 89 the day before.
Looking For The Best Stocks To Buy And Watch? Start Here
IBD's unique rating measures market leadership with a 1 (worst) to 99 (best) score. The grade shows how a stock's price behavior over the last 52 weeks compares to all the other stocks in our database.
History shows that the market's biggest winners typically have an RS Rating of over 80 at the beginning of a new price run.
GRAIL has climbed more than 5% past a 21.47 entry in a first-stage cup without handle, meaning it's now out of a proper buy zone. Look for the stock to create a new chance to pick up shares like a three-weeks tight or pullback to the 50-day or 10-week line.
GRAIL posted 0% earnings growth in the latest quarterly report, while sales growth came in at 11%.
GRAIL earns the No. 12 rank among its peers in the Medical-Services industry group. GeneDx Holdings, Hims & Hers Health and InfuSystem Holdings are among the top 5 highly rated stocks within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
Stocks With Rising Relative Strength Ratings
